Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GERALD STEPHEN GREER

Allopathic & Osteopathic Physicians Internal Medicine Clinical Cardiac Electrophysiology

NPI
1811943400
CMS profile
309617
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$921.34

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $921.34 62

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GERALD STEPHEN GREER

NPI 1811943400 · CMS profile ID 309617

Allopathic & Osteopathic Physicians / Internal Medicine / Clinical Cardiac Electrophysiology

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811943400?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GERALD STEPHEN GREER, NPI 1811943400, CMS profile ID 309617. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811943400?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GERALD STEPHEN GREER, NPI 1811943400, CMS profile ID 309617. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811943400?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GERALD STEPHEN GREER, NPI 1811943400, CMS profile ID 309617, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1811943400?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $921.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $11.8402/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932629565 CMS
Janssen Pharmaceuticals, Inc $14.8402/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885681555 CMS
Novartis Pharmaceuticals Corporation $10.3002/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893714335 CMS
PFIZER INC. $12.1402/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949069509 CMS
Novartis Pharmaceuticals Corporation $10.8201/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893714333 CMS
Janssen Pharmaceuticals, Inc $13.8501/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885681549 CMS
Janssen Pharmaceuticals, Inc $6.5901/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885681543 CMS
Janssen Pharmaceuticals, Inc $11.7701/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885681591 CMS
E.R. Squibb & Sons, L.L.C. $12.7501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932629563 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16.6701/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876395165 CMS
Merck Sharp & Dohme LLC $14.3501/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944093975 CMS
PFIZER INC. $11.3101/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949412687 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,372.37 115
PY2020 $7,023.35 52
PY2021 $1,297.89 104
PY2022 $921.34 62
PY2023 $3,025.98 25
PY2024 $1,326.16 24
PY2025 $2,385.25 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $193,039.91 41
PY2024 Principal investigator $186,877.30 11
PY2022 Principal investigator $1,843.75 4
PY2021 Principal investigator $9,029.90 11
PY2020 Principal investigator $29,389.16 10
PY2019 Recipient $373.35 2
PY2019 Principal investigator $52,762.62 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $64.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669776
Principal investigator 1 CSL Behring $120.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669778
Principal investigator 1 CSL Behring $700.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669780
Principal investigator 1 CSL Behring $1,200.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669782
Principal investigator 1 CSL Behring $1,400.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669784
Principal investigator 1 CSL Behring $1,750.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669786
Principal investigator 1 CSL Behring $700.00 09/03/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.52 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.34 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $252.30 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $296.26 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $296.26 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184207687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.48 06/18/2025 Non-covered Recipient Entity
ARKANSAS CARDIOLOGY P A
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184208661
Principal investigator 1 CSL Behring $2,907.00 05/23/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669736
Principal investigator 1 CSL Behring $18,919.20 05/06/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669838
Principal investigator 1 CSL Behring $16.75 04/28/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669854
Principal investigator 1 CSL Behring $9,459.60 04/15/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669836
Principal investigator 1 CSL Behring $145.12 04/15/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669850
Principal investigator 1 CSL Behring $1,169.00 04/09/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669730
Principal investigator 1 CSL Behring $40,203.30 04/08/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669834
Principal investigator 1 CSL Behring $95.39 03/31/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669822
Principal investigator 1 CSL Behring $754.47 03/31/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669824
Principal investigator 1 CSL Behring $550.00 03/31/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669826
Principal investigator 1 CSL Behring $1,379.00 03/14/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669728
Principal investigator 1 CSL Behring $28,378.80 03/11/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669832
Principal investigator 1 CSL Behring $1,200.00 03/10/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669722
Principal investigator 1 CSL Behring $2,600.00 03/10/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669724
Principal investigator 1 CSL Behring $6,282.00 03/10/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669726
Principal investigator 1 CSL Behring $152.70 02/21/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669848
Principal investigator 1 CSL Behring $242.64 02/20/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669846
Principal investigator 1 CSL Behring $11,944.00 02/19/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669720
Principal investigator 1 CSL Behring $28,378.80 02/11/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669830
Principal investigator 1 CSL Behring $1,508.94 02/10/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669818
Principal investigator 1 CSL Behring $275.00 02/10/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669820
Principal investigator 1 CSL Behring $9,500.00 01/15/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669716
Principal investigator 1 CSL Behring $18,919.20 01/14/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669828
Principal investigator 1 CSL Behring $550.00 01/13/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669796
Principal investigator 1 CSL Behring $115.50 01/13/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669798
Principal investigator 1 CSL Behring $181.98 01/07/2025 Non-covered Recipient Entity
Arkansas Cardiology, P.A.
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252669840